Strides Pharma Science shares rose by 2% in early trade on September 25 due to its subsidiary obtaining USFDA approval for a cardiac drug. The stock was priced at Rs 509.95, up by Rs 11.30 (2.27%) on the BSE during early trade.
Strides Pharma Global Pte Limited, a subsidiary, received USFDA approval for Icosapent Ethyl Capsules (0.5 gram and 1 gram), a medication used in conjunction with other drugs to reduce cardiovascular risks. The product is bioequivalent and therapeutically equivalent to Vascepa (Reference Listed Drug) and will be produced in Bengaluru.
Strides Pharma has a significant number of approved ANDAs (Abbreviated New Drug Applications) with the USFDA and plans to launch around 60 new products in the US within three years. Earlier in the month, the subsidiary received tentative approval for its New Drug Application (NDA) and Dolutegravir tablets from the USFDA, both to be manufactured in Bengaluru.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.